GB1581776A - Vaccines against oedema disease of piglets - Google Patents
Vaccines against oedema disease of piglets Download PDFInfo
- Publication number
- GB1581776A GB1581776A GB33499/77A GB3349977A GB1581776A GB 1581776 A GB1581776 A GB 1581776A GB 33499/77 A GB33499/77 A GB 33499/77A GB 3349977 A GB3349977 A GB 3349977A GB 1581776 A GB1581776 A GB 1581776A
- Authority
- GB
- United Kingdom
- Prior art keywords
- neurotoxin
- coli
- piglets
- oedema disease
- piglet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010030113 Oedema Diseases 0.000 title claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 24
- 229960005486 vaccine Drugs 0.000 title claims description 12
- 239000002581 neurotoxin Substances 0.000 claims description 40
- 231100000618 neurotoxin Toxicity 0.000 claims description 40
- 101710138657 Neurotoxin Proteins 0.000 claims description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 239000012062 aqueous buffer Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 3
- 229940001007 aluminium phosphate Drugs 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 229920005654 Sephadex Polymers 0.000 claims description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical group O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000000287 crude extract Substances 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 238000005185 salting out Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000029182 enterotoxemia Diseases 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71574676A | 1976-08-18 | 1976-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1581776A true GB1581776A (en) | 1980-12-17 |
Family
ID=24875314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB33499/77A Expired GB1581776A (en) | 1976-08-18 | 1977-08-10 | Vaccines against oedema disease of piglets |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4136181A (enExample) |
| JP (1) | JPS5324011A (enExample) |
| BE (1) | BE857794A (enExample) |
| DE (1) | DE2737060C2 (enExample) |
| FR (2) | FR2361913A1 (enExample) |
| GB (1) | GB1581776A (enExample) |
| NL (1) | NL7709085A (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH639852A5 (fr) * | 1979-07-26 | 1983-12-15 | Om Laboratoires Sa | Medicament contre les maladies infectieuses des voies urinaires et digestives. |
| JPH0314650Y2 (enExample) * | 1981-04-15 | 1991-04-02 | ||
| US4465665A (en) * | 1982-03-04 | 1984-08-14 | Smithkline-Rit | Detoxified E. coli neurotoxin, preparation thereof and immunological preparations containing it |
| US4428931A (en) | 1982-03-15 | 1984-01-31 | Merck & Co., Inc. | Bacterial toxoids and gram-negative immune globulin therefrom |
| US5552144A (en) * | 1992-01-22 | 1996-09-03 | Microcarb, Inc. | Immunogenic shiga-like toxin II variant mutants |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2125533A (en) * | 1934-01-12 | 1938-08-02 | Cutter Lab | Biologicals |
| US3208909A (en) * | 1961-05-19 | 1965-09-28 | Puziss Milton | Anaerobic process for production of a gel-adsorbed anthrax immunizing antigen |
| FR2227861B1 (enExample) * | 1973-05-04 | 1976-07-02 | Anvar | |
| US4002736A (en) * | 1974-12-16 | 1977-01-11 | Pankratz Duane C | Porcine bacterin |
| US4053584A (en) * | 1975-02-12 | 1977-10-11 | Recherche Et Industrie Therapeutiques | Pre-farrowing pregnant sow piglet colibacillosis vaccines and process for their administration to pregnant sows before farrowing |
| GB1560934A (en) * | 1975-05-07 | 1980-02-13 | Unilever Ltd | Methods for the resistance of non-human mammals to gastro-intestinal disorders |
-
1977
- 1977-08-10 GB GB33499/77A patent/GB1581776A/en not_active Expired
- 1977-08-11 JP JP9689977A patent/JPS5324011A/ja active Granted
- 1977-08-11 FR FR7724759A patent/FR2361913A1/fr active Granted
- 1977-08-16 BE BE180174A patent/BE857794A/xx not_active IP Right Cessation
- 1977-08-17 NL NL7709085A patent/NL7709085A/xx not_active Application Discontinuation
- 1977-08-17 DE DE2737060A patent/DE2737060C2/de not_active Expired
- 1977-12-29 US US05/865,451 patent/US4136181A/en not_active Expired - Lifetime
-
1980
- 1980-04-10 FR FR8008050A patent/FR2448902A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6141324B2 (enExample) | 1986-09-13 |
| NL7709085A (nl) | 1978-02-21 |
| BE857794A (fr) | 1978-02-16 |
| US4136181A (en) | 1979-01-23 |
| FR2448902A1 (fr) | 1980-09-12 |
| FR2448902B1 (enExample) | 1983-05-20 |
| JPS5324011A (en) | 1978-03-06 |
| FR2361913B1 (enExample) | 1983-06-24 |
| FR2361913A1 (fr) | 1978-03-17 |
| DE2737060C2 (de) | 1986-07-31 |
| DE2737060A1 (de) | 1978-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ibrahim et al. | Method for the isolation of highly purified Salmonella flagellins | |
| US4271147A (en) | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same | |
| Njoku-Obi et al. | Production and nature of Listeria monocytogenes hemolysins | |
| EP0024956B1 (en) | Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype, method of preparing them and bacterial strains used in them | |
| Angerman et al. | Comparative efficacy and toxicity of a ribosomal vaccine, acetone-killed cells, lipopolysaccharide, and a live cell vaccine prepared from Salmonella typhhimurium | |
| US5618541A (en) | Vaccine against Neisseria meningitidis infections | |
| CN102917730A (zh) | 修饰的脑膜炎球菌fHBP多肽 | |
| Andrewes et al. | Influenza: further experiments on the active immunization of mice | |
| EP0041897B1 (en) | Polysaccharide antigen from streptococcus and vaccines | |
| Oguma et al. | Antigenicity of converting phages obtained from Clostridium botulinum types C and D | |
| US3855408A (en) | Poultry vaccine | |
| Baba | Immunogenic activity of a ribosomal fraction obtained from Pasteurella multocida | |
| CA1206905A (en) | Process for the production of capsular polyosides and capsular polyosides obtained thereby | |
| Newman et al. | Separation of serum bactericidal and opsonizing activities for Haemophilus influenzae type b | |
| GB1581776A (en) | Vaccines against oedema disease of piglets | |
| US4053584A (en) | Pre-farrowing pregnant sow piglet colibacillosis vaccines and process for their administration to pregnant sows before farrowing | |
| EP0354628B1 (en) | Vaccine suitable for prophylaxis and control, respectively, of the pig disease caused by Haemophilus pleuropneumoniae as well as a method for its production | |
| US4248862A (en) | Immunogenic cell envelope preparations | |
| Kimura et al. | Studies on the pathogenesis of streptococcal infection in cultured yellowtails, Seriola spp.: effect of crude exotoxin fractions from cell‐free culture on experimental streptococcal infection | |
| Barta | Soluble protective antigen from Bordetella pertussis prepared with sodium desoxycholate | |
| WO1989000860A1 (en) | Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli | |
| DE69633179T2 (de) | Transferrinrezeptorgene | |
| US3793150A (en) | Equine strangles vaccine and method of preparing and using the same | |
| US4465665A (en) | Detoxified E. coli neurotoxin, preparation thereof and immunological preparations containing it | |
| EP1387693B1 (en) | Saponin inactivated mycoplasma vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee | ||
| PCPE | Delete 'patent ceased' from journal |
Free format text: NO.4907,PAGE 906 |
|
| PCNP | Patent ceased through non-payment of renewal fee |